Dong Wang

Dong Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
YZYang Zheng
Yang Zheng
KWKai Wang
Kai Wang
YOYong Ou
Yong Ou
XHXu Hu
Xu Hu
ZWZiyan Wang
Ziyan Wang
SRShangqing Ren
Shangqing Ren

30 May 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYang Zheng
Yang Zheng
HPHeling Peng
Heling Peng
XHXu Hu
Xu Hu
YOYong Ou
Yong Ou
DWDong Wang
Dong Wang
SRShangqing Ren
Shangqing Ren
Introduction: Urachal carcinoma (UrC) is a rare and aggressive disease. Systematic chemotherapy shows limited efficacy in patients with advanced disease, while targeted therapy and immunotherapy may provide a reasonable alternative for specific populations. The molecular pattern of colorectal cancer (CRC) have recently been identified; this understanding has significantly influenced the clinical management of CRC in terms of molecular-targeted therapy. Although some genetic alterations have been associated with UrC, there is still no systematic overview of the molecular profile of this rare malignancy.Methods: In this review, we comprehensively discuss the molecular profile of UrC and further identify potential targets for the personalized treatment of UrC as well as immune checkpoint inhibitors that represent underlying biomarkers. A systematic literature search was carried out by searching the PubMed, EMBASE, and Web of Science databases to identify all literature related to targeted therapy and immunotherapy in urachal carcinoma from inception to February 2023.Results: A total of 28 articles were eligible, and most studies included were case report sand retrospective case series. Furthermore, 420 cases of UrC were identified to analyze the association between mutations and UrC. The most commonly mutated gene in UrC was TP53 with the prevalence of 70%, followed by KRAS mutations in 28.3%, MYC mutations in 20.3%, SMAD4 mutations in 18.2% and GNAS mutations in 18%, amongst other genes.Discussion: The molecular patterns of UrC and CRC are similar yet distinct. Notably, targeted therapy, especially EGFR-targeting therapy, might provide curative efficacy for patients with UrC by applying specific molecular markers. Additional potential biomarkers for the immunotherapy of UrC are mismatch repair (MMR) status and PD-L1 expression profile. In addition, combined regimens featuring targeted agents and immune checkpoint blockers might increase antitumor activity and exert better efficacy in UrC patients with specific mutational burden.

10 November 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
JYJiazheng Yuan
Jiazheng Yuan
QHQinyu He
Qinyu He
YZYang Zheng
Yang Zheng
QLQian Lv
Qian Lv
XHXu Hu
Xu Hu
SRShangqing Ren
Shangqing Ren

13 March 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
SRShangqing Ren
Shangqing Ren
YZYang Zheng
Yang Zheng
XHXu Hu
Xu Hu
YBYige Bao
Yige Bao
DWDong Wang
Dong Wang
YCYifan Chang
Yifan Chang

29 November 2024 in Medicine
Verified
Journal Article
Open access
BYBo Yang
Bo Yang
YZYang Zheng
Yang Zheng
MZMengqin Zheng
Mengqin Zheng
DWDong Wang
Dong Wang
SRShangqing Ren
Shangqing Ren
JTJingzhi Tian
Jingzhi Tian
Radiofrequency ablation (RFA) has been proposed for T1a renal cell carcinoma (RCC). The present study compared partial nephrectomy (PN) with RFA for T1a RCC stratified by tumor sizes. We selected patients with RCC and underwent PN or RFA through the surveillance, epidemiology, end results (SEER) database. The Kaplan–Meier method and Cox proportional hazards regression model were conducted. Inverse probability of treatment weights was conducted for sensitivity analysis. We enrolled 15,692 patients in the unmatched cohort, 15,392 (98.1%) underwent PN, and 300 (1.9%) underwent RFA. For tumor ≦ 2 cm, PN was equal to RFA in terms of overall survival (OS) (P > .05) and cancer-specific survival (CSS) (P > .05). For tumor size 2 to 3 cm, PN is likely to have a better OS (P < .05)and comparable CSS (P > .05). For > 3 cm tumor, PN might be associated with higher OS (P < .05) and CSS (P < .05) compared with RFA. In conclusion, PN had a similar OS and CSS compared with RFA in tumor size ≦ 2 cm, RFA could be offered for elderly or patients with comorbidity. For > 2 cm tumors, RFA is not recommended. However, further randomized controlled trials are further required to validate our results.

19 June 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
THTing Hu
Ting Hu
FZFang Zhou
Fang Zhou
YZYang Zheng
Yang Zheng
BLBohan Luo
Bohan Luo
YZYongliang Zhang
Yongliang Zhang
DWDong Wang
Dong Wang
Introduction: Effective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression. Due to the lack of a head-to-head comparison of darolutamide (DARO) and abiraterone acetate plus prednisone (AAP) doublet regimen, this study aims to compare the efficacy and safety of DARO + ADT and AAP + ADT in the treatment of mHSPC in the real world.Methods: This study retrospectively analyzed patients with mHSPC who received DARO or AAP treatment in Sichuan Provincial People’s Hospital from January 2022 to June 2024, with follow-up until December 2024. The clinical data and prostate-specific antigen (PSA) changes of patients were collected. The primary endpoint was time to metastatic castration-resistant prostate cancer (mCRPC), and the secondary endpoints were overall survival (OS), radiological progression-free survival (rPFS), time to PSA progression, time to pain progression, and time to subsequent prostate cancer therapy.Results: A total of 178 patients were included, with 96 in the DARO group and 82 in the AAP group. The baseline characteristics of the two groups were comparable. The median follow-up time and interquartile ranges of the DARO and AAP groups were 12.0 [7.9–17.6] months and 17.4 [9.3–23.8] months, respectively. For the primary endpoint, DARO significantly delayed the time to mCRPC versus AAP [HR, 0.41 (95%CI, 0.23 to 0.71); P < 0.005]. And the DARO group significantly benefited in all secondary endpoints. DARO significantly led to deeper PSA reduction compared to AAP, with higher median reduction rates, better PSA50 and PSA90 remission rates, and a higher proportion of patients reaching lower PSA values. The incidence of adverse reactions was similar in the two groups, and there was no grade 3 or above drug-related adverse reactions.Conclusion: In the treatment of mHSPC, DARO + ADT was associated with significant improvement of clinical outcomes versus AAP + ADT, while their safety is comparable.